High-dose chemotherapy for patients with stage III breast cancer with homologous recombination deficiency: a discrete choice experiment among healthcare providers

Background and purpose: High-dose chemotherapy with autologous stem cell rescue (HDCT) is currently under investigation as a potential therapy for patients with stage III HER2-negative breast cancer with homologous recombination deficiency (HRD). In addition to survival, the impact on short- and lon...

Full description

Saved in:

Bibliographic Details
Published in:	Acta oncologica Vol. 63; no. 1; pp. 701 - 709
Main Authors:	Verbeek, Joost G.E., Azarang, Leyla, Pilli, Luis E., De Jong, Vincent M.T., Jager, Agnes, Linn, Sabine C., Retèl, Valesca P., Van Harten, Wim H.
Format:	Journal Article
Language:	English
Published:	Sweden MJS Publishing on behalf of Acta Oncologica 10.09.2024 Medical Journals Sweden
Subjects:	Adult Aged Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use BRCA1 Protein BRCA2 Protein Breast neoplasms Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - pathology Choice Behavior Conjoint Analysis Discrete Choice Experiment Female Health Personnel - psychology Homologous Recombination Humans Middle Aged Neoplasm Staging Original Receptor, ErbB-2 - metabolism
ISSN:	1651-226X, 0284-186X, 1651-226X
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!